Abstract

UCSF researchers have developed a platform capable of producing mAbs that target post-translational modifications such as phosphorylation. The technology could open up a host of new targets for cancer and other diseases associated with aberrant modifications. Next, the team will have to show that the mAbs target endogenous proteins in vivo.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call